DEVELOPMENT SAFETY UPDATE REPORT - ICH
The Development Safety Update Report (DSUR) proposed in this guideline is intended to be a common standard for periodic reporting on drugs under development (including
Download DEVELOPMENT SAFETY UPDATE REPORT - ICH
Information
Domain:
Source:
Link to this page:
Documents from same domain
ICH HARMONISED TRIPARTITE GUIDELINE
www.ich.orgGOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting
Final Concept Paper Q12: Technical and Regulatory ...
www.ich.orgFINAL Q12 Concept Paper Endorsed: 9 September 2014 -3- product lifecycle management. To date, the main emphasis has been on the implementation of
Q7 Implementation Working Group ICH Q7 …
www.ich.orgInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, P.O. Box 195, 1211 Geneva 20, Switzerland
GUIDELINE FOR GOOD CLINICAL PRACTICE
www.ich.orgGUIDELINE FOR GOOD CLINICAL PRACTICE INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the
ICH HARMONISED GUIDELINE
www.ich.orgE6(R1) Document History First Codification History Date New Codification November 2005 E6 Approval by the Steering Committee under Step 2 and release for public consultation.
ICH HARMONISED GUIDELINE - ICH Official web …
www.ich.orginternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised guideline guideline for elemental impurities
![[ICH E2F] [EXAMPLE DSUR – PHASE III …](/cache/preview/1/3/5/f/e/1/c/f/thumb-135fe1cf2cdb82799c462ad0ea089c48.jpg)
[ICH E2F] [EXAMPLE DSUR – PHASE III …
www.ich.orgfictional document for illustrative purposes only document date: 5 october 2010 [ich e2f] [example dsur – phase iii investigational drug] zb3579
ADDENDUM TO ICH E11: CLINICAL INVESTIGATION …
www.ich.org3 ICH HARMONISED GUIDELINE ADDENDUM TO ICH E11: CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION E11 (R1) ICH Consensus Guideline Released for Adoption on 18 August 2017, at Step 4 of the ICH
M4Q Implementation Working Group Questions & …
www.ich.org1. Introduction This document is intended to provide additional guidance for the preparation of an application file in the CTD-Q format (see section 2: General Issues).
I ADDENDUM TO ICH E6(R1 ... - ICH Official web site
www.ich.orgi ICH HARMONISED GUIDELINE INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE ICH E6(R2) Draft ICH Consensus Guideline Released for Consultation on 11 June 2015, at Step 2 of the ICH Process
Related documents
Medicinal products quality, safety and efficacy - Trends
academy.gmp-compliance.orgEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Medicinal products – quality, safety and efficacy Brussels, 12 October …
Kava: a review of the safety of traditional and ...
www.fao.orgKava: a review of the safety of traditional and recreational beverage consumption . Food and Agriculture Organization of the United Nations . World Health Organization
Government response to the UK Early Access to Medicines ...
www.mhra.gov.uk1 . Government response to the UK Early Access to Medicines Scheme consultation – March 2014
DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND …
www.ema.europa.eudirective 2001/83/ec of the european parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use
Guideline on plasma-derived medicinal products
www.ema.europa.euPlasma-derived medicinal products, collection and control of starting materials (plasma master file), manufacture, quality control, process validation, virus
GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC ...
www.who.intPage 4 the licensing of these products will facilitate development of and worldwide access to biotherapeutics of assured quality, safety and efficacy at more affordable prices.
Environmental Monitoring of Clean Rooms in Vaccine ...
www.who.intPage 5 of 37 In a strict interpretation of the WHO GMP for sterile pharmaceutical products annex, for sterile bacterial and viral vaccines where heat sterilization or filtration are impossible due